A5030652345- Asthma and respiratory diseases
- Inhalation and Respiratory Drug Delivery
- Respiratory and Cough-Related Research
- Bone health and treatments
- Antibiotics Pharmacokinetics and Efficacy
- Pharmaceutical studies and practices
- Chemotherapy-induced organ toxicity mitigation
- Analytical Methods in Pharmaceuticals
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Drug Transport and Resistance Mechanisms
- Adrenal Hormones and Disorders
- Metal complexes synthesis and properties
- Allergic Rhinitis and Sensitization
- Poisoning and overdose treatments
- Pharmacological Effects and Assays
- Pharmacological Effects and Toxicity Studies
- Hormonal and reproductive studies
- Drug-Induced Hepatotoxicity and Protection
- Pesticide Residue Analysis and Safety
- Respiratory Support and Mechanisms
- Medical Imaging and Pathology Studies
- Stress Responses and Cortisol
- Delphi Technique in Research
- Fibroblast Growth Factor Research
- Hemoglobinopathies and Related Disorders
Oldham Council
2024
GlaxoSmithKline (United Kingdom)
2011-2022
GlaxoSmithKline (India)
2017
Weatherford College
2011
West Middlesex University Hospital
2002
Quest Diagnostics (United Kingdom)
2002
University College Hospital
2002
University College London
2002
Life Cycle Engineering (United States)
2002
Wellcome Library
2000-2001
Aims To assess the absolute bioavailability, pharmacokinetics and metabolism of beclomethasone dipropionate (BDP) in man following intravenous, oral, intranasal inhaled administration. Methods Twelve healthy subjects participated this seven‐way cross‐over study where BDP was administered via routes: intravenous infusion (1000 µg), oral (4000 µg, aqueous suspension), (1344 nasal spray) µg ex‐valve, metered dose inhaler). The contribution lung, nose gut to systemic exposure assessed by...
Aims To compare the airway potency, systemic activity and therapeutic index of three inhaled corticosteroids that differ in glucocorticoid receptor binding affinity, physicochemical pharmacokinetic properties. Methods This escalating‐dose, placebo‐controlled, cross‐over study randomised adults with asthma to 1 or 2 treatment periods ≥25 days washout in‐between. Each period comprised five 7‐day dose escalations (μg/d): fluticasone furoate (FF; 25 → 100 200 400 800), propionate (FP; 50 500...
Asthma treatment guidelines classify inhaled corticosteroid (ICS) regimens as low, medium, or high dose. However, efficacy and safety are not independently assessed accordingly. Moreover, differences in ICS duration of action considered when a dose regimen is selected. We investigated the implications these limitations for available molecules. Published pharmacodynamic pharmacokinetic parameters were used, alongside physiological pharmacological principles, to estimate Extent glucocorticoid...
1. Linezolid (ZYVOX), the first of a new class antibiotics, oxazolidinones, is approved for treatment Gram-positive bacterial infections. 2. The aim was to determine absorption, distribution, metabolism and excretion (ADME) linezolid in mouse, rat dog support preclinical safety studies clinical development. 3. Conventional replicate study designs were employed animal experiments, biofluids assayed by HPLC or HPLC-MS. 4. rapidly absorbed after p.o. dosing with an bioavailability > 95% dog,...
Aims To measure and compare the systemic bioavailability of fluticasone propionate aqueous nasal spray a new drop formulation, using sensitive analytical method high dose regimen. Methods Volunteers received four 800 µg doses as or drops over 2 days, separated by an 8 h interval. On day 2, blood samples were collected for assay plasma concentrations. Results The mean exposure, both formulations was 8.5 pg ml −1 (drops) 67.5 (spray). Mean absolute bioavailabilities estimated to be 0.06% 0.51%...
In April 2010 a workshop on the "Role of Pharmacokinetics in Establishing Bioequivalence for Orally Inhaled Drug Products" was sponsored by Product Quality Research Institute (PQRI) coordination with Respiratory Delivery (RDD) 2010. The objective to evaluate current state knowledge and identify gaps information relating potential use pharmacokinetics (PK) as key indicator vivo bioequivalence (BE) locally acting orally inhaled products (OIPs). addition, strengths limitations PK approach...
Aims We have previously shown that the systemic exposure to inhaled fluticasone propionate (FP) is reduced in asthmatics compared with healthy subjects. now its pharmacokinetics patients suffering from chronic obstructive pulmonary disease (COPD, n = 10) and matched subjects ( 13). Methods A double‐blind, randomized, cross‐over study design was used. Plasma FP serum cortisol were measured for 12 h after received hydrofluoroalkane 1000 µg day −1 (via an MDI spacer) 7 days following a single...
Background: The object of this study was to assess whether a capsule-based and multidose dry powder inhaler containing salmeterol (as xinafoate salt) 50 μg plus fluticasone propionate (FP) 250 [combination (SFC 50/250)] could be equivalent in terms vivo drug delivery systemic exposure. Methods: This randomized, double-blind, double-dummy, replicate treatment design comparative bioavailability SFC 50/250 delivered (Rotahaler®) (Diskus®). Subjects with asthma or chronic obstructive pulmonary...
Poor adherence to inhaled drug therapy in individuals with asthma and/or chronic obstructive pulmonary disease (COPD) may be associated suboptimal therapeutic outcomes. Measurement of residues hair samples has been employed assess oral medication use over time. Here, we test the feasibility analyzing from patients COPD for assessing prescribed medication. In total, 200 male and female subjects, ≥ 18 years age, stable who were receiving an acceptable standard care daily product consistently,...